Newton, MA, United States of America

Brent Morse

USPTO Granted Patents = 4 


Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 90(Granted Patents)


Location History:

  • Newton Center, MA (US) (2013)
  • Newton, MA (US) (2016 - 2020)

Company Filing History:


Years Active: 2013-2020

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Brent Morse: Innovator in Targeted Therapeutics

Introduction

Brent Morse is a notable inventor based in Newton, MA (US). He has made significant contributions to the field of targeted therapeutics, particularly through his work on engineered proteins that bind to the epidermal growth factor receptor (EGFR). With a total of 4 patents to his name, Morse's innovations are paving the way for advancements in diagnostic, research, and therapeutic applications.

Latest Patents

Morse's latest patents focus on single domain proteins that bind to EGFR. These inventions not only relate to the proteins themselves but also encompass their use in various applications, including diagnostics and therapeutics. Furthermore, his patents include cells that comprise these proteins, polynucleotides encoding such proteins or fragments thereof, and vectors that contain the polynucleotides encoding these innovative proteins.

Career Highlights

Brent Morse is currently associated with Bristol-Myers Squibb Company, where he continues to push the boundaries of medical science. His work is instrumental in developing targeted therapies that can significantly improve patient outcomes.

Collaborations

Morse collaborates with esteemed colleagues such as Ray Camphausen and Stuart Emanuel, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Brent Morse's contributions to the field of targeted therapeutics exemplify the impact of innovative thinking in medicine. His work on engineered proteins is set to revolutionize the way we approach treatment for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…